Pyrrolopyrazine derivatives
US5292732A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jun 26, 1992 |
| Grant date | Mar 8, 1994 |
| Priority date | — |
| Expiry date | Jun 26, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The novel pyrrolopyrazines of the general formula ##STR1## wherein one of R.sup.1 and R.sup.2 signifies aryl and the other signifies hydrogen, lower alkyl or aryl or R.sup.1 and R.sup.2 together with the two carbon atoms denoted by .alpha. and .beta. signify the group A; ##STR2## R.sup.3 signifies hydrogen or lower alkyl and R.sup.4 signifies hydrogen or PA0 R.sup.3 and R.sup.4 together signify an additional C/N bond; PA0 R.sup.5 signifies hydrogen or lower alkyl; PA0 R.sup.6 signifies hydrogen or lower alkyl; PA0 R.sup.7 signifies hydrogen, halogen, lower alkyl, optionally substituted lower alkoxy, or C.sub.3-6 -cycloalkyl, C.sub.4-6 -cycloalkenyl, C.sub.3-6 -cycloalkyloxy, hydroxy, trifluoro- methanesulphonyloxy or optionally substituted benzyl- oxycarbonyloxy; and the dotted line signifies an optional additional C/C bond, and pharmaceutically acceptable acid addition salts of the compounds of formula I can be used in the control or prevention of illnesses or in the improvement of health, especially in the control or prevention of depressive states, cognitive disorders and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.